We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IMV Doses First Patient in the Mid-Stage Study With Keytruda
Read MoreHide Full Article
IMV Inc. recently announced that the first patient has been dosed in the phase IIB VITALIZE study.
The study will further evaluate the clinical benefit of IMV’s lead compound, maveropepimut-S (MVP-S), in combination with pharma giant Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda, in patients with relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL).
The study will also evaluate the contribution of low-dose cyclophosphamide (CPA) as an immune modulator.
The study is designed to assess MVP-S in combination with Keyruda with or without CPA in stages. The combination will be evaluated in up to 150 subjects with r/r DLBCL who have received at least two prior lines of systemic therapy and are ineligible or have failed autologous stem cell transplant (ASCT) or CAR-T therapy.
The primary endpoint is objective response rate (ORR), centrally evaluated per Lugano (2014) and measured by the number of subjects per arm achieving the best response of partial or complete response (PR+CR) during the two-year treatment period. All subjects will be evaluated for their baseline PD-L1 expression. Exploratory endpoints include cell-mediated immune response, tumor immune cell infiltration and biomarker analysis.
IMV expects to review early data in summer 2022.
MVP-S is also being evaluated for hematologic and solid cancers, including DLBCL and ovarian, bladder and breast cancers.
Shares of IMV have plunged 63% in the past year compared with the industry’s decline of 27.1%.
Image Source: Zacks Investment Research
IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A phase I study in bladder cancer will open in early 2022.
The successful development of the candidates will be a significant boost for this clinical-stage company.
On Sep 30, 2021, IMV had cash and cash equivalents of $36.5 million and working capital of $37.3 million. The company expects that its current cash position will be sufficient to fund operations until the third quarter of 2022.
Merck’s Keytruda is approved for various oncology indications and is one of the key drivers for the company. Keytruda raked in sales of $12.6 billion in the first nine months of 2021.
Image: Bigstock
IMV Doses First Patient in the Mid-Stage Study With Keytruda
IMV Inc. recently announced that the first patient has been dosed in the phase IIB VITALIZE study.
The study will further evaluate the clinical benefit of IMV’s lead compound, maveropepimut-S (MVP-S), in combination with pharma giant Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda, in patients with relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL).
The study will also evaluate the contribution of low-dose cyclophosphamide (CPA) as an immune modulator.
The study is designed to assess MVP-S in combination with Keyruda with or without CPA in stages. The combination will be evaluated in up to 150 subjects with r/r DLBCL who have received at least two prior lines of systemic therapy and are ineligible or have failed autologous stem cell transplant (ASCT) or CAR-T therapy.
The primary endpoint is objective response rate (ORR), centrally evaluated per Lugano (2014) and measured by the number of subjects per arm achieving the best response of partial or complete response (PR+CR) during the two-year treatment period. All subjects will be evaluated for their baseline PD-L1 expression. Exploratory endpoints include cell-mediated immune response, tumor immune cell infiltration and biomarker analysis.
IMV expects to review early data in summer 2022.
MVP-S is also being evaluated for hematologic and solid cancers, including DLBCL and ovarian, bladder and breast cancers.
Shares of IMV have plunged 63% in the past year compared with the industry’s decline of 27.1%.
IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A phase I study in bladder cancer will open in early 2022.
The successful development of the candidates will be a significant boost for this clinical-stage company.
On Sep 30, 2021, IMV had cash and cash equivalents of $36.5 million and working capital of $37.3 million. The company expects that its current cash position will be sufficient to fund operations until the third quarter of 2022.
Merck’s Keytruda is approved for various oncology indications and is one of the key drivers for the company. Keytruda raked in sales of $12.6 billion in the first nine months of 2021.
IMV currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector are Vir Biotechnology (VIR - Free Report) and Alkermes (ALKS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings estimates for Vir have moved up $4.76 in the past 30 days for 2022. VIR is up 9.6% in the past year.
Earnings estimates for Alkermes have moved up a cent for 2022 in the past 30 days for 2022. ALKS is up 10.1% in the past year.